Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 2/2010

01.11.2010

Incidence of very high defibrillation thresholds (DFT) and efficacy of subcutaneous (SQ) array insertion during implantable cardioverter defibrillator (ICD) implantation

verfasst von: Atul Verma, Alexander J. Kaplan, Bradley Sarak, Richard Oosthuizen, Marianne Beardsall, Jan Higgenbottam, Zaev Wulffhart, Yaariv Khaykin

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The incidence, risk factors, and management of very high defibrillation thresholds (DFTs) during present-day implantable cardioverter defibrillator (ICD) testing are not well known.

Objectives

The purpose of this study was to assess (1) the incidence of very high DFTs and (2) the efficacy/safety of routinely adding a subcutaneous (SQ) array for these patients.

Methods

The study evaluated patients undergoing first-time ICD implantation at Southlake Regional Healthcare Centre from January 2006 to December 2007. All implanted ICDs had a maximal output of 35 J. Patients with DFTs greater than a 10-J safety margin from maximum output were considered to have very high readings and underwent SQ array insertion after other attempts at lowering DFT (group I). These patients were compared with the rest of the patients who had acceptable DFTs (group II) using both univariate and multivariate logistic regression analysis. Outcomes of array insertion were also assessed.

Results

A total of 313 patients underwent first-time ICD implantation during the analysis period. Of those, 16 (5.1%) had very high DFTs (group I). By univariate analysis, advanced New York Heart Association class (3 or 4), congestive heart failure hospitalization, non-ischemic cardiomyopathy, amiodarone use, implant of a biventricular device, and highest quartile of left ventricular (LV) chamber enlargement were all significant predictors of very high DFTs (p < 0.05). By multivariate analysis, only amiodarone use [odds ratio (OR) = 10.3, 95% confidence interval (95% CI) = 3.7–32.6] and being in the highest quartile for LV diastolic diameter [OR = 5.4, 95% CI = 1.4–20.8] predicted very high DFT. In all 16 cases, other methods to lower DFT prior to array insertion were attempted but failed for all patients: reversing shock polarity (n = 15), removing the superior vena cava coil (n = 14), reprogramming shock waveform (n = 9), and repositioning right ventricular lead (n = 9). Addition of the array successfully decreased DFT to within safety margin for all patients (33 ± 2 vs 21 ± 5 J, p = 0.02). Complication due to array insertion occurred in one patient (pneumothorax).

Conclusions

Very high DFTs occur in about 5% of patients undergoing ICD implantation and may be predicted by LV dilation and amiodarone use. SQ array insertion reliably corrects this problem over other interventions with a low rate of procedural complication.
Literatur
1.
Zurück zum Zitat Pires, L. A., & Johnson, K. M. (2006). Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? Journal of Cardiovascular Electrophysiology, 17(2), 140–145.CrossRefPubMed Pires, L. A., & Johnson, K. M. (2006). Intraoperative testing of the implantable cardioverter-defibrillator: how much is enough? Journal of Cardiovascular Electrophysiology, 17(2), 140–145.CrossRefPubMed
2.
Zurück zum Zitat Russo, A. M., Sauer, W., Gerstenfeld, E. P., et al. (2005). Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm, 2(5), 456–461.CrossRefPubMed Russo, A. M., Sauer, W., Gerstenfeld, E. P., et al. (2005). Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm, 2(5), 456–461.CrossRefPubMed
3.
Zurück zum Zitat Gold, M. R., Higgins, S., Klein, R., et al. (2002). Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation, 105(17), 2043–2048.CrossRefPubMed Gold, M. R., Higgins, S., Klein, R., et al. (2002). Efficacy and temporal stability of reduced safety margins for ventricular defibrillation: primary results from the Low Energy Safety Study (LESS). Circulation, 105(17), 2043–2048.CrossRefPubMed
4.
Zurück zum Zitat Kuhlkamp, V., Dornberger, V., Khalighi, K., et al. (1998). Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing and Clinical Electrophysiology, 21(12), 2596–2605.CrossRefPubMed Kuhlkamp, V., Dornberger, V., Khalighi, K., et al. (1998). Effect of a single element subcutaneous array electrode added to a transvenous electrode configuration on the defibrillation field and the defibrillation threshold. Pacing and Clinical Electrophysiology, 21(12), 2596–2605.CrossRefPubMed
5.
Zurück zum Zitat Trusty, J. M., Hayes, D. L., Stanton, M. S., et al. (2000). Factors affecting the frequency of subcutaneous lead usage in implantable defibrillators. Pacing and Clinical Electrophysiology, 23(5), 842–846.CrossRefPubMed Trusty, J. M., Hayes, D. L., Stanton, M. S., et al. (2000). Factors affecting the frequency of subcutaneous lead usage in implantable defibrillators. Pacing and Clinical Electrophysiology, 23(5), 842–846.CrossRefPubMed
6.
Zurück zum Zitat Ideker, R. E., Epstein, A. E., & Plumb, V. J. (2005). Should shocks still be administered during implantable cardioverter-defibrillator insertion? Heart Rhythm, 2(5), 462–463.CrossRefPubMed Ideker, R. E., Epstein, A. E., & Plumb, V. J. (2005). Should shocks still be administered during implantable cardioverter-defibrillator insertion? Heart Rhythm, 2(5), 462–463.CrossRefPubMed
7.
Zurück zum Zitat Theuns, D. A., Szili-Torok, T., & Jordaens, L. J. (2005). Defibrillation efficacy testing: long-term follow-up and mortality. Europace, 7(6), 509–515.CrossRefPubMed Theuns, D. A., Szili-Torok, T., & Jordaens, L. J. (2005). Defibrillation efficacy testing: long-term follow-up and mortality. Europace, 7(6), 509–515.CrossRefPubMed
8.
Zurück zum Zitat Mainigi, S. K., & Callans, D. J. (2006). How to manage the patient with a high defibrillation threshold. Heart Rhythm, 3(4), 492–495.CrossRefPubMed Mainigi, S. K., & Callans, D. J. (2006). How to manage the patient with a high defibrillation threshold. Heart Rhythm, 3(4), 492–495.CrossRefPubMed
9.
Zurück zum Zitat Day, J. D., Olshansky, B., Moore, S., et al. (2008). High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. Europace, 10(3), 347–350.CrossRefPubMed Day, J. D., Olshansky, B., Moore, S., et al. (2008). High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. Europace, 10(3), 347–350.CrossRefPubMed
10.
Zurück zum Zitat Hodgson, D. M., Olsovsky, M. R., Shorofsky, S. R., et al. (2002). Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing and Clinical Electrophysiology, 25(4 Pt 1), 408–413.CrossRefPubMed Hodgson, D. M., Olsovsky, M. R., Shorofsky, S. R., et al. (2002). Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing and Clinical Electrophysiology, 25(4 Pt 1), 408–413.CrossRefPubMed
11.
Zurück zum Zitat Lubinski, A., Lewicka-Nowak, E., Zienciuk, A., et al. (2005). Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators. Kardiologia Polska, 62(4), 317–328. discussion 329–331.PubMed Lubinski, A., Lewicka-Nowak, E., Zienciuk, A., et al. (2005). Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators. Kardiologia Polska, 62(4), 317–328. discussion 329–331.PubMed
12.
Zurück zum Zitat Shukla, H. H., Flaker, G. C., Jayam, V., et al. (2003). High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. Pacing and Clinical Electrophysiology, 26(1 Pt 1), 44–48.CrossRefPubMed Shukla, H. H., Flaker, G. C., Jayam, V., et al. (2003). High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. Pacing and Clinical Electrophysiology, 26(1 Pt 1), 44–48.CrossRefPubMed
13.
Zurück zum Zitat Birnie, D., Tung, S., Simpson, C., et al. (2008). Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm, 5(3), 387–390.CrossRefPubMed Birnie, D., Tung, S., Simpson, C., et al. (2008). Complications associated with defibrillation threshold testing: the Canadian experience. Heart Rhythm, 5(3), 387–390.CrossRefPubMed
14.
Zurück zum Zitat Hohnloser, S. H., Dorian, P., Roberts, R., et al. (2006). Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 114(2), 104–109.CrossRefPubMed Hohnloser, S. H., Dorian, P., Roberts, R., et al. (2006). Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation, 114(2), 104–109.CrossRefPubMed
15.
Zurück zum Zitat Bollmann, A., Husser, D., & Cannom, D. S. (2005). Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. American Journal of Cardiovascular Drugs, 5(6), 371–378.CrossRefPubMed Bollmann, A., Husser, D., & Cannom, D. S. (2005). Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. American Journal of Cardiovascular Drugs, 5(6), 371–378.CrossRefPubMed
16.
Zurück zum Zitat Schuger, C., Ellenbogen, K. A., Faddis, M., et al. (2006). Defibrillation energy requirements in an ICD population receiving cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 17(3), 247–250.CrossRefPubMed Schuger, C., Ellenbogen, K. A., Faddis, M., et al. (2006). Defibrillation energy requirements in an ICD population receiving cardiac resynchronization therapy. Journal of Cardiovascular Electrophysiology, 17(3), 247–250.CrossRefPubMed
17.
Zurück zum Zitat Kettering, K., Mewis, C., Dornberger, V., et al. (2004). Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Pacing and Clinical Electrophysiology, 27(10), 1355–1361.CrossRefPubMed Kettering, K., Mewis, C., Dornberger, V., et al. (2004). Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Pacing and Clinical Electrophysiology, 27(10), 1355–1361.CrossRefPubMed
18.
Zurück zum Zitat Zienciuk, A., Lubinski, A., Krolak, T., et al. (2007). Effects of shock polarity reversal on defibrillation threshold in an implantable cardioverter-defibrillator. Kardiologia Polska, 65(5), 495–500. discussion 501–492.PubMed Zienciuk, A., Lubinski, A., Krolak, T., et al. (2007). Effects of shock polarity reversal on defibrillation threshold in an implantable cardioverter-defibrillator. Kardiologia Polska, 65(5), 495–500. discussion 501–492.PubMed
19.
Zurück zum Zitat Keane, D., Aweh, N., Hynes, B., et al. (2007). Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. Pacing and Clinical Electrophysiology, 30(5), 596–602.CrossRefPubMed Keane, D., Aweh, N., Hynes, B., et al. (2007). Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. Pacing and Clinical Electrophysiology, 30(5), 596–602.CrossRefPubMed
20.
Zurück zum Zitat Blatt, J. A., Poole, J. E., Johnson, G. W., et al. (2008). No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). Journal of the American College of Cardiology, 52(7), 551–556.CrossRefPubMed Blatt, J. A., Poole, J. E., Johnson, G. W., et al. (2008). No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). Journal of the American College of Cardiology, 52(7), 551–556.CrossRefPubMed
Metadaten
Titel
Incidence of very high defibrillation thresholds (DFT) and efficacy of subcutaneous (SQ) array insertion during implantable cardioverter defibrillator (ICD) implantation
verfasst von
Atul Verma
Alexander J. Kaplan
Bradley Sarak
Richard Oosthuizen
Marianne Beardsall
Jan Higgenbottam
Zaev Wulffhart
Yaariv Khaykin
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 2/2010
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-010-9511-7

Weitere Artikel der Ausgabe 2/2010

Journal of Interventional Cardiac Electrophysiology 2/2010 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.